ACC

This channel contains news about the American College of Cardiology (ACC), including coverage of its annual meeting and links to recently released practice guidelines. The ACC is a leading resource for cardiology professionals, including all its subspecialties. 

Medicare will pay for telehealth virtual doctor visits during the duration of the coronavirus COVID-19 outbreak.
News | Cardiovascular Business | March 17, 2020
March 17, 2020 — The Trump Administration today announced expanded Medicare telehealth coverage that will enable...
Videos | Coronavirus (COVID-19) | March 17, 2020
Interview with Thomas Maddox, M.D., MSc, FACC, the chairman of the American College of Cardiology (ACC) Science and...
ACC issues document outlining COVID-19 Implications For Patients With Underlying Cardiovascular Conditions. The COVID-19 mortality rate for patients cardiovascular disease is 10.5 percent based of data from Chinese hospitals since the outbreak. COVID-19 fatality rates for patients with comorbidities are higher than the average population, but cardiac patients had the highest death rate. #COVID19 #coronavirus #2019nCoV #SARS‐CoV‐2

The COVID-19 mortality rate for patients cardiovascular disease is 10.5 percent based of data from Chinese hospitals since the outbreak. COVID-19 fatality rates for patients with comorbidities are higher than the average population, but cardiac patients had the highest death rate.

Feature | Coronavirus (COVID-19) | March 09, 2020
March 9, 2020 — The American College of Cardiology (ACC) is offering updates on the clinical impact of novel...
ACC Cancels 2020 Conference Amid Coronavirus Concerns. #COVID19 #coronavirus #2019nCoV
Feature | ACC | March 09, 2020 | Dave Fornell, Editor
March 9, 2020 — Less than week after the American College of Cardiology (ACC) said it would push ahead with holding its...
American College of Cardiology Names Douglas Drachman Next Annual Scientific Session Vice Chair

Image courtesy of Massachusetts General Hospital

News | ACC | October 08, 2019
October 8, 2019 — Douglas Drachman, M.D., FACC, has been selected as the next vice chair of the American College of...
Videos | Artificial Intelligence | June 20, 2019
John Rumsfeld, M.D., Ph.D., FACC, American College Cardiology (ACC) chief innovation officer, and professor of medicine...
Study Finds Only Six Percent of Patients Taking Statins as Directed
News | Antiplatelet and Anticoagulation Therapies | April 18, 2019
April 18, 2019 — A recent study found patients with atherosclerotic cardiovascular disease cut their risk of a second...
Sponsored Content | Videos | Information Technology | April 17, 2019
With Intellispace Enterprise Edition as the foundation, Philips Healthcare is connecting facilities and service areas...
HeartHero Personal Automated External Defibrillator Wins ACC.19 Innovation Challenge
News | Defibrillator Monitors | April 05, 2019
April 5, 2019 — Medical device startup HeartHero was the winner in the Innovation Challenge at the 2019 American...
 Evolut Low Risk Trial compared the minimally invasive Evolut transcatheter aortic valve replacement (TAVR) system to the gold standard of open-heart surgery in characteristically younger, healthier aortic stenosis patients. The randomized trial, which met its primary non-inferiority endpoint of all-cause mortality or disabling stroke at two years compared to surgery (5.3 vs. 6.7 percent; posterior probability of non-inferiority >0.999), was presented at the American College of Cardiology (ACC) 2019 meeting
News | Heart Valve Technology | April 03, 2019
April 3, 2019 – The ACC.19 late-breaking landmark Evolut Low Risk Trial compared the minimally invasive Evolut...
Diabetes Drug Effective Against Heart Failure in Wide Spectrum of Patients
News | Heart Failure | March 29, 2019
March 29, 2019 — The cardiovascular benefits of the diabetes drug dapagliflozin extend across a wide spectrum of...
Vascepa Markedly Reduces First, Repeat and Total Cardiovascular Events
News | Pharmaceuticals | March 29, 2019
March 29, 2019 — Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and...
New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/valsartan (Entresto) continued to deliver reductions in the heart failure biomarker N-terminal pro–B-type natriuretic peptide (NT-proBNP), an established biomarker for heart failure severity and prognosis.[1] The data was presented as a late-breaker at the American College of Cardiology (ACC) 2019 Annual Scientific Session in March.
News | Heart Failure | March 27, 2019
March 27, 2019 —New data from a four-week extension of the landmark PIONEER-HF Trial showed the drug sacubitril/...
SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions. FFR in the cath lab.

SyncVision iFR Co-registration from Philips Healthcare maps pressure readings onto angiogram. Results from an international study presented at ACC 2019 indicates pressure readings obtained using iFR (instantaneous wave-free ratio, also referred to as instant wave-free ratio or instant flow reserve) in coronary arteries may localize stenoses that remain after interventions.

Feature | ACC | March 27, 2019 | Greg Freiherr, Contributing Editor
The fingerprints of value-added medicine were all over products and works-in-progress on the exhibit floor of the...
Videos | Wearables | March 26, 2019
Khaldoun Tarakji, M.D., MPH, staff physician in the Section of Electrophysiology and Pacing in the Robert and Suzanne...